The 7 most recent market catalysts affecting $DRMA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 17, 2026
Corporate Catalyst
Neutral
Impact 55
Dermata Therapeutics Highlights Additional Clinical Results for Tome Foundational Treatment
Dermata Therapeutics disclosed additional positive results from a cosmetic clinical study for its Tome Foundational Treatment. These findings, which highlight improvements in skin …
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is Dermata Therapeutics Stock Gaining Thursday?
Dermata Therapeutics (DRMA) reported positive topline results from a cosmetic clinical study for its Tome Foundational Treatment, a recently launched skincare product. The study sh…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 75
Dermata Therapeutics shares are trading higher after the company reported study results showing skin appearance improvements with its Tome Foundational Treatment.
This headline represents a significant corporate catalyst for Dermata Therapeutics. Positive clinical trial results for a foundational treatment can dramatically alter a biotechnol…
Oct 15, 2026
Corporate Catalyst
Bullish
Impact 65
Dermata Therapeutics Announces Over 71% Of Patients Had Overall Skin Improvements At Day 29 In Its Cosmetic Clinical Trial Of Tome Foundational Treatment
Dermata Therapeutics (DRMA) reported positive topline results from a cosmetic clinical study for its Tome Foundational Treatment. The study, involving 31 participants, showed that …
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 75
Dermata Therapeutics Announces $3.4M Private Placement Of 2,293,608 Shares And Warrants Priced At-The-Market At $1.46 Per Share
This private placement is a significant event for Dermata Therapeutics, as it injects $3.4 million into the company, providing much-needed capital for R&D, clinical trials, or gene…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
12 Health Care Stocks Moving In Tuesday's After-Market Session
This filing details the after-market performance of 12 health care stocks, with gains and losses largely attributed to the release of Q2 earnings reports. The immediate impact is s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.